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Abstract
Background: Annexin A7 is a Ca2+- and phospholipid-binding protein expressed as a 47 and 51
kDa isoform, which is thought to be involved in membrane fusion processes. Recently the 47 kDa
isoform has been identified in erythrocytes where it was proposed to be a key component in the
process of the Ca2+-dependent vesicle release, a process with which red blood cells might protect
themselves against an attack by for example complement components.
Results: The role of annexin A7 in red blood cells was addressed in erythrocytes from anxA7-/-
mice. Interestingly, the Ca2+-mediated vesiculation process was not impaired. Also, the membrane
organization appeared not to be disturbed as assessed using gradient fractionation studies. Instead,
lack of annexin A7 led to an altered cell shape and increased osmotic resistance of red blood cells.
Annexin A7 was also identified in platelets. In these cells its loss led to a slightly slower aggregation
velocity which seems to be compensated by an increased number of platelets. The results appear
to rule out an important role of annexin A7 in membrane fusion processes occurring in red blood
cells. Instead the protein might be involved in the organization of the membrane cytoskeleton. Red
blood cells may represent an appropriate model to study the role of annexin A7 in cellular
processes.
Conclusion: We have demonstrated the presence of both annexin A7 isoforms in red blood cells
and the presence of the small isoform in platelets. In both cell types the loss of annexin A7 impairs
cellular functions. The defects observed are however not compatible with a crucial role for annexin
A7 in membrane fusion processes in these cell types.
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Background
Annexin A7 is a Ca2+- and phospholipid-binding protein,
which was isolated as the agent that mediated aggregation
of chromaffin granules and fusion of phospholipid mem-
branes in the presence of Ca2+. This activity led to the pro-
posal of annexin A7's involvement in the exocytotic
secretion of catecholamines [1]. The protein belongs to a
family of evolutionarily conserved proteins of a bipartite
structure with a variable N-terminal and a conserved C-
terminal domain. The C-terminal domain is responsible
for the Ca2+- and phospholipid-binding, the N-terminal
domain appears to confer functional diversity [2-4]. The
binding to negatively charged phospholipids is thought to
be mediated by Ca2+ ions.
Annexin A7 is unique in that it carries an extraordinarily
long and hydrophobic amino terminus with more than
100 amino acids. Alternative splicing gives rise to two iso-
forms of 47 and 51 kDa. Both isoforms differ by an addi-
tional cassette exon located in the first third of the N-
terminal domain. Most tissues harbor only the 47 kDa
isoform, both forms are found in brain and heart, while
the large isoform is exclusively expressed in mature skele-
tal muscle.
At the cellular level annexin A7 can be detected in the
cytosol, at the plasma membrane, around the nucleus, at
vesicular structures including adrenal chromaffin gran-
ules, and at the t-tubule system [5,6]. Annexin A7 translo-
cates to membranes in a Ca2+-dependent fashion and,
when intracellular Ca2+ levels rise, sequentially redistrib-
utes to the plasma and the nuclear membrane as well as to
intracellular vesicles. Furthermore, annexin A7 associates
with lipid rafts [7]. Lipid rafts play a key role in membrane
budding and in vesiculation processes such as endo- and
exocytosis [8-10].
Two binding partners of annexin A7 have been identified,
sorcin and galectin-3 [11-13]. Sorcin is a Ca2+-binding
protein and belongs to the penta EF-hand protein family
[14]. Like annexin A7 it binds to membranes in a Ca2+-
dependent manner. Sorcin also has been described as
interaction partner of the ryanodine receptor, and appears
to modulate its function [15]. The influence of the sorcin/
annexin A7 interaction on the ryanodine receptor is
unknown. Sorcin and annexin A7 are coexpressed in all
tissues examined so far [11]. The binding of annexin A7
and sorcin is Ca2+-dependent and occurs at micromolar
Ca2+ concentrations. The binding sites have been localised
to the amino terminal GGYY and GYGG motifs in sorcin
and to the GYPP motif in the amino terminus of annexin
A7. The proteins bind to each other with a stoichiometry
of two sorcin molecules per annexin A7 molecule [12].
Galectin-3 is a multifunctional oncogenic protein with an
anti-apoptotic activity found in the extracellular space, in
the nucleus and cytoplasm and in mitochondria. Cyto-
plasmic galectin-3 correlates with tumor progression and
protects mitochondrial integrity. Down regulation of
annexin A7 prevents galectin-3 translocation to the peri-
nuclear membrane and increases galectin-3 secretion. For
annexin A7 a role for galectin-3 trafficking, apoptosis reg-
ulation, and mitochondrial integrity was proposed [13].
The cellular role of annexin A7 is not well understood. It
is thought to regulate and stabilize membrane domains
and to have a role in Ca2+ homeostasis and Ca2+-depend-
ent signaling pathways. These proposals are supported by
data obtained from analysis of annexin A7 deficient
mouse mutants. Two annexin A7 129Sv null mice strains
were generated independently using a different strategy.
The one of Srivastava et al. [16] is lethal. Heterozygous
mice exhibit an insulin secretion defect and tumor pheno-
types. The null strain reported by Herr et al. [17] is viable,
healthy, and shows no insulin secretion defect or other
obvious defects. However, in isolated cardiomyocytes the
frequency-induced shortening is disturbed. Here we have
focused on the analysis of red blood cells and platelets of
the anxA7-/- mutant. Generally, red blood cells and plate-
lets were thought not to contain annexin A7 and only
recently the 47 kDa isoform has been reported as compo-
nent of red blood cells [7].
Red blood cells undergo various biochemical or morpho-
logical changes that appear to be Ca2+-dependent proc-
esses [18,19]. One of them is the release of hemoglobin-
containing exovesicles occurring in vivo as well as in vitro
[7,20]. This process is thought to represent a protective
method of the red blood cell against an attack by for
example complement components. Red blood cells which
lack the ability to vesiculate cause a disease with red blood
cell destruction and haemoglobinuria [21]. There exist
two types of vesicles, micro- and nanovesicles with a size
of 180 nm and 60 nm, respectively. They are enriched in
cholesterol and sphingolipid rich lipid raft domains that
are associated with proteins like acetylcholinesterase, cell
surface proteins including a complement receptor, and
the lipid raft proteins stomatin and flotillin, but they lack
any cytoskeletal protein [7]. Furthermore, they contain
sorcin and annexin A7 attached to the lipid rafts. Both
proteins are more abundant in nanovesicles. The vesicle
formation goes along with several other changes in the red
blood cell like cytoskeletal rearrangements and changes in
the phospholipid orientation in the cellular membrane.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/8
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Results
Annexin A7 expression in red blood cells, red blood cell 
derived exovesicles and in platelets
Salzer et al. recently reported the presence of the 47 kDa
isoform of annexin A7 and its partner sorcin in micro- and
nanovesicles derived from red blood cells where they are
located in the lumen and are also enriched in membrane
rafts [7]. We have now extended these findings and show
here that the 51 kDa isoform is present as well. In western
blots of human red blood cells the 47 and 51 kDa iso-
forms were detected using mAb 203–217 (Fig. 1). The 47
kDa isoform was detected in silver stained gels and its
identity with annexin A7 confirmed by peptide mass fin-
gerprinting (data not shown). The 51 kDa isoform was
only detected in western blots.
Its presence in vesicles led to the suggestion, that, along
with raft domains, annexin A7 plays a role in membrane
organization and the vesiculation process. To examine
this, we analysed the ability of red blood cells derived
from the annexin A7 knock out mice (anxA7-/-) to form
exovesicles. Because of better accessibility and larger avail-
able amounts that led to clear results, we included our
data obtained with human blood. Independent of the
presence of annexin A7 both types of exovesicles, micro-
and nanovesicles, were released after Ca2+/ionophore
treatment as determined by acetylcholine esterase activity
and microscopic examination. Annexin A7 is present in
both vesicle types where it is more enriched in nanovesi-
cles (Fig. 2). The 51 kDa isoform is only detectable in
nanovesicles. The quantity of both vesicle types did not
differ between wild type and knock out red blood cell ves-
icles as determined by the AChE-values (A405 nanovesi-
cles: ~0.18; A405 microvesicles: ~0.9; both, for wt and ko).
It appears that annexin A7, although it has been described
to fuse membranes, is not a key component in the process
of the formation of red blood cell exovesicles. When we
probed for the presence of sorcin in wild type and mutant
vesicles we found that the sorcin levels were reduced in
the mutant nanovesicles (Fig. 2).
To study the distribution of annexin A7 in red blood cells
we used self forming iodixanol density gradients. Both
isoforms were present in the soluble fraction as well as in
the gradient fractions where they are assumed to be asso-
ciated with membranes. These membranes are exclusively
plasma membranes as red blood cells are free of any
organelles. The distribution was however not homogene-
ous throughout the gradient. This could reflect the bind-
ing of annexin A7 to membrane subdomains that have
different lipid or lipid/protein composition as discussed
by Salzer et al. [7]. Likewise, sorcin does not exhibit a
homogeneous distribution in the gradient. Moreover, it
segregates into vesicles which are not associated with
annexin A7 (Fig. 3). We also tested platelets for annexin
A7 expression and detected the 47 kDa isoform (Fig. 1).
The lack of annexin A7 changes red blood cell morphology 
and osmotic resistance
As annexin A7 is a component of red blood cell vesicles we
studied the consequences of the loss of the protein in the
anxA7-/-mouse for red blood cell morphology and
osmotic resistance. In a standard 'blood smear' we did not
note a deformation of the cells, however dark field micro-
scopy revealed changes in shape and diameter of the
anxA7-/-red blood cells. They had a statistically significant
larger cell diameter of 6.0 µm compared to wild type with
5.7 µm (p = 0.015, n = 40), a remarkably lower empha-
sized central impression and a more flat shape (Fig. 4). No
significant change in the mean corpuscular volume
(MCV) was measured with the ADVIA 120 cell counter.
Shape and MCV of a red blood cell essentially influence its
function and capillary passage. The typical biconcave
form depends on various influences including the mem-
brane lipid composition and the submembranous
cytoskeleton [32] where annexin A7 might play a role. The
Expression of annexin A7 in human red blood cells (1) and  human platelets (2) Figure 1
Expression of annexin A7 in human red blood cells (1) and 
human platelets (2). Protein homogenates were separated by 
SDS-PAGE (12 % acrylamide). The resulting western blot was 
probed with mAb 203–217, visualization was by a secondary 
peroxidase coupled antibody followed by ECL. Both isoforms 
are detected in red blood cells, in platelets only the small iso-
form is present.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/8
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osmotic resistance, which is the resistance towards
changes in the extracellular ionic strength, is a convenient
assay for analysis of the red blood cell integrity. It is meas-
ured as the sodium chloride concentration at which cellu-
lar lysis starts (minimal resistance) up to a complete lysis
(maximal resistance) of the cells [33]. Osmotic resistance
increases with higher MCV, larger surface area and a
higher degree of cellular metabolism stabilizing the intra-
cellular ion levels. Aged red blood cells show a lowered
MCV and lower osmotic resistance [33]. Similar proper-
ties can be observed in red blood cells with lowered mem-
brane permeability. The osmotic resistance of annexin A7
deficient red blood cells is significantly increased com-
pared to wild type cells. The minimal resistance value of
knock out cells is observed in a 0.60 % NaCl solution ver-
sus 0.65 % for wild type cells. 50 % haemolysis is achieved
at 0.516 % NaCl solution for knock out versus 0.564 %
Enrichment of annexin A7 and sorcin in exovesicles derived from red blood cells Figure 2
Enrichment of annexin A7 and sorcin in exovesicles derived from red blood cells. Vesicles from wild type (wt) and anxA7-/- 
mutant (ko) were generated with Ca2+/ionophore treatment, isolated by differential centrifugation and analysed by immunob-
lotting with mAb 203–217 and a sorcin polyclonal antibody. In general, annexin A7 and sorcin are more abundant in nanovesi-
cles. The 51 kDa isoform of annexin A7 (arrows) is only observed in nanovesicles. Samples of both vesicles types were 
normalized according to their acetylcholine esterase activity. Human red blood cells (co) were used for control and normalized 
independently.
Association of annexin A7 and sorcin with distinct red blood cell plasma membrane fractions Figure 3
Association of annexin A7 and sorcin with distinct red blood cell plasma membrane fractions. Lysed human red blood cells 
were added to a self forming iodixanol density gradient. The density of the gradient increases from left (1.06 g/ml) to right 
(1.20 g/ml). Fractions were analysed by immunoblotting using mAb 203–217 and the sorcin polyclonal antibody.
Dark field microscopy of red blood cells from anxA7-/- mutant  (B) and wild type mice (A) Figure 4
Dark field microscopy of red blood cells from anxA7-/- mutant 
(B) and wild type mice (A). The mean cellular diameters are 
6.0 µm and 5.7 µm, respectively. The size differences are sta-
tistically significant (p = 0.015; n = 40). Bar, 3 µm.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/8
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NaCl for wild type cells (mean values, p = 0.00066, n = 8;
Fig. 5). The resistance width of the knock out cells is
slightly lower (0.20 % instead of 0.25 % NaCl solution).
We also performed direct measurements of the red blood
cell membrane deformability, to further characterize a
possible role of annexin A7 on the membrane stability.
With micropipette experiments we tried to correlate
mechanical characteristics of the red blood cells with their
morphology. We could not observe any statistically signif-
icant difference of values describing membrane rigidity
and lysis force in these experiments (M. Heil, B. Hoff-
mann and R. Merkel, unpublished results). However, the
distinction observed in the osmotic resistance experi-
ments was highly significant and reflects a mean value
over a high number of different red blood cells.
These data suggest that annexin A7 contributes to the
shape of red blood cells and the osmotic resistance. As we
have not observed a binding of annexin A7 to F-actin
(data not shown) it could do so either by alteration of the
membrane rigidity and/or by affecting the ion
homeostasis.
The lack of annexin A7 affects primary haemostasis ex vivo
The use of an advanced electronic cell counter/flow
cytometer (ADVIA 120) allowed us to screen other param-
eters as well despite of the limited murine blood volume.
We analysed leukocytes, red blood cells, haemoglobin
content, haematocrit, mean cellular volume, mean cellu-
lar haemoglobin, mean cellular haemoglobin concentra-
tion, platelets, neutrophiles, lymphocytes, monocytes,
eosinophiles and basophiles. In these tests of whole
blood we found only a change in the platelet numbers,
whereas all other haematological parameters were not
affected. The mean platelet counts from wild type and
anxA7-/- mutant mice are determined as 674 × 103/µl and
774 × 103/µl, respectively. The platelet counts in knock
out mice are significantly higher (p = 0.0275; n knock out =
Osmotic resistance curves of red blood cells from wild type and anxA7-/- mutant mice Figure 5
Osmotic resistance curves of red blood cells from wild type and anxA7-/- mutant mice. The osmotic resistance towards changes 
in the extracellular ionic strength is a convenient assay for analysis of the red blood cell integrity. It is measured as a sodium 
chloride concentration in which cellular lysis starts (minimal resistance) up to a complete lysis (maximal resistance) of a red 
blood cell. The osmotic resistance of annexin A7 deficient red blood cells is significantly increased compared to the one of wild 
type (p = 0.00066; n = 8).BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/8
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11, n wild type = 14). An increase in platelet counts is a rather
uncommon disorder. In humans, platelet counts nor-
mally increase only transiently as in reactive thrombocy-
tosis and under postoperative conditions or are largely
increased in neoplastic diseases. By contrast, the anxA7-/-
mice are healthy and viable. Therefore we tested the plate-
let function and performed aggregometry measurements
with platelet rich plasma. Platelet activation is observed as
a morphological change from the resting discoid state to
activated spherical cells with pseudopods. The morpho-
logical changes are due to cytoskeletal rearrangements. In
vitro the activated cells form aggregates recruiting addi-
tional cells in the solution thereby reducing its cloudiness.
Analysis of the transmission values of aggregation curves
after platelet activation by ristocetin addition (von Wille-
brand cofactor) showed that both curves differed
significantly at the time point of seven seconds after plate-
let initiation (p = 0.0287, n knock out = 16, n wild type = 15; Fig.
6). Annexin A7 deficient platelets showed a slightly low-
ered aggregation velocity. When we compared the aggre-
gation curves of human platelets from a healthy donor
with the ones obtained from an individual with a von Wil-
lebrand factor type 1 defect, we found that the difference
in the curves was much more pronounced as observed in
our studies of healthy mouse platelets and anxA7-/-plate-
lets. Furthermore we found that murine platelets
responded immediately to the initiating chemical whereas
human platelets have a lag phase [23].
Discussion
Annexin A7 is thought to have a role in vesicle fusion and
in regulating and stabilizing membrane domains [1]. The
protein has been localized to the plasma membrane
including raft subdomains, furthermore it is present in the
Platelet aggregation curves from platelet rich plasma of annexin A7 knock out and wild type mice Figure 6
Platelet aggregation curves from platelet rich plasma of annexin A7 knock out and wild type mice. The transmission values 
were measured with an APACT photometer and aggregation was initiated by adding ristocetin. The first thirty seconds are 
given. Constant platelet counts were used throughout all experiments. The aggregation curve data were analysed for slope val-
ues, the maximal aggregation amplitude of every single curve was set to 100 %. Both murine curves differ significantly at a time 
point of seven seconds after platelet initiation, the mutant shows a slightly lower aggregation velocity (p = 0.0287, n knock out = 
16, n wild type = 15, mean knock out = 67.7 % transmission, mean wild type = 77.1 % transmission, standard error knock out = 8.3 % 
transmission, standard error wild type = 13.8 % transmission). Murine platelets react immediately to the initiating chemical and 
show no lag phase like the normal human platelets. For comparison of the range of the platelet impairment slightly affected 
human platelets are shown as well (von Willebrand syndrome).BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/8
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cytosol where it is found on subcellular vesicle-like struc-
tures. This distribution appears to be independent of the
tissue or cell type analysed. In specialized or terminally
differentiated cells, expression levels increase and fre-
quently the larger of the two isoforms is being expressed
[6,34,35].
Red blood cells, which were thought to be devoid of
annexin A7, were recently shown to harbor the 47 kDa
isoform together with its binding partner sorcin [7]. We
showed the presence of the 51 kDa isoform as well, add-
ing red blood cells to the list of cells that harbor this iso-
form. Salzer et al. [7] not only demonstrated the presence
of annexin A7 in red blood cells, they also showed that
annexin A7 and sorcin were enriched in membrane raft
domains of nanovesicles formed from red blood cells in
vitro. Raft domains in general are considered key players
in membrane organization and in mediating the
vesiculation process. They result from the clustering of
sphingolipids and cholesterol in the outer leaflet of the
membrane connected to phospholipids and cholesterol
in the inner leaflet and are enriched in special proteins.
Biochemically rafts are defined as membranes that are
resistant to extraction by cold Triton X-100 and can be
floated to low densities in sucrose gradient centrifugation
[36].
The findings of Caohuy et al. [37] that annexin A7 medi-
ates membrane aggregation also suggested that annexin
A7 is an essential component during vesiculation. In addi-
tion they reported a further activation of the vesiculation
process by GTP and proposed that annexin A7 acts as a
GTPase. Similarly, the presence of GTP enhanced the
secretion of surfactant by annexin A7. These results were
thought to support a direct role for annexin A7 in sur-
factant secretion, but in these studies annexin A7 medi-
ated membrane fusion was separated from a second GTP-
dependent mechanism [38].
Having an annexin A7 knockout mouse we tested the
involvement of annexin A7 in budding of red blood cell
vesicles. Our data suggest that the efficiency of micro- and
nanovesicle formation is not significantly different in wild
type and mutant red blood cells. Likewise, Dictyostelium
discoideum  cells, in which the single annexin gene was
inactivated, were not impaired in processes requiring
membrane fusion [[39]; and data unpublished]. It might
well be that the observed fusion of phospholipid layers by
annexin A7 in the presence of high Ca2+ concentrations
may turn out to be an in vitro effect. Similarly, the high
abundance of annexin A7 in micro- and nanovesicles
might be fortuitous as a significant percentage of the red
blood cell membrane, with which annexin A7 associates
when the Ca2+ levels rise, appears to be involved in the for-
mation of exovesicles. Furthermore, the distribution of
both annexin A7 isoforms in gradients of red blood cells
indicates a function which differs from organizing subcel-
lular membranes or membrane pathways. Whereas
annexin A2 is tightly associated with endosomes and may
have functions in membrane fusion and the endosomal
pathway, annexin A7 distributes with plasma membrane
raft domains of different types and densities. Interestingly,
in vesicles of red blood cells lacking annexin A7 the
amount of sorcin is lowered, indicating that its localisa-
tion is affected by the loss of annexin A7 or its expression
during red blood cell development was reduced.
Having excluded a direct role in vesicle formation and
membrane fusion, annexin A7 might act by its property as
Ca2+-binding protein [17]. Previous results in which
annexin A7 was shown to play a role in membrane aggre-
gation might be explained by a supportive function of
annexin A7 in that it interferes with the local Ca2+ home-
ostasis thus influencing membrane organization. As the
annexins belong to a wide spread and evolutionarily con-
served protein family, redundant, but not identical func-
tions are expected. However, so far no other members of
the annexin family, which may substitute for annexin A7,
have been described in red blood cells.
The structural basis for the elasticy of red blood cells in cir-
culation are long range molecular functions of the plasma
membrane and the membrane associated part of the
cytoskeleton [40-43]. Major constituents of the mem-
brane skeleton are spectrin tetramers linked together by
short actin filaments and several other proteins covering
the entire cytoplasmic surface of the red blood cell
membrane [44]. Membrane cholesterol diminishes red
blood cell haemolysis by the complement complex,
whereas depletion of raft cholesterol abrogates associa-
tion of all raft proteins with no significant effect on areas
in the rest of the cell membrane and deformability
[45,46].
Annexin A7 knock out mouse red blood cells show a more
flat shape and have a higher osmotic resistance. The pres-
ence of annexin A7 may alter the membrane flexibility in
that it supports the typical biconcave membrane shape
and leads to a lower minimal osmotic resistance. Annexin
A7 does not appear to have an influence on plasma mem-
brane integrity itself as the maximal osmotic resistance
value stays constant. Ca2+ and membrane skeletal proteins
are known to play key roles on the red blood cell mem-
brane shape and stability [47]. Annexins have been
reported to bind directly to F-actin, we could however
exclude such an activity for annexin A7. Nevertheless it
might interact with other components and have a role in
organizing the membrane cytoskeleton, controlling raft
protein associations or influencing the ionic strength ofBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/8
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red blood cells on its own or by interfering with other sig-
naling pathways.
As discussed above annexin A7 could be involved in the
cytoplasmic Ca2+ homeostasis. It has been demonstrated
that micromolar changes of the intracellular Ca2+ concen-
tration exert a profound effect on the membrane proper-
ties that regulate red blood cell deformability [48,49].
Furthermore, the intracellular Ca2+ was shown to regulate
the membrane stability through modulation of cytoskele-
tal protein interactions [50]. Ca2+ also induces a transbi-
layer phospholipid redistribution inducing a shape
change of red blood cells [51]. In addition, Ca2+ ions can
drive spiculation of the membrane bilayer without involv-
ing the cytoskeleton [52].
We have also observed a defect in platelet function in the
annexin A7 mutant. In the platelet aggregation experi-
ments the initial aggregation velocity was slightly, but sig-
nificantly lower in platelets lacking annexin A7. These
data are not reflected by a change in the in vivo bleeding
time. However the reaction speed of murine platelets is
much higher than those of human and due to the techni-
cal setup we might have missed larger changes in the
mouse samples. The immediate reaction of mouse plate-
lets and the absence of a lag phase after triggering may be
caused by an immediately initiated thrombin generation
[22]. As known from the frequent human vWF-syndrome
or other haemostatic diseases, small defects often are clin-
ically silent and do not result in physiological changes
under normal conditions. Only in situations with severe
physical injury, distinct environmental influences or addi-
tional platelet attributes like the platelet antigen polymor-
phism [53] differences might become apparent.
Conclusions
In this paper we report the presence of both annexin A7
isoforms in red blood cells where they are abundant in
nanovesicles that form upon Ca2+ addition. The proteins
are however not required for the vesiculation process.
They are also not essential for the formation of specific
membrane domains such as lipid rafts, as exogenously
added recombinant annexin A7 redistributed to similar
positions in a density gradient containing membranes
derived from red blood cells of anxA7-/-mice. The
observed cell shape change of erythrocytes lacking
annexin A7 might be due to alterations in the erythrocyte
cytoskeleton. As a direct interaction with F-actin was ruled
out, this effect might be mediated by annexin's Ca2+-bind-
ing activity.
Methods
Acquisition of murine and human blood samples
Blood from 129Sv wild type and annexin A7 knock out
mice (anxA7-/-) kept under pathogen-free conditions and
fed with regular food, was collected in 1 ml syringes with
a 22 gauge needle punctating the right cardiac ventricle
immediately after they had been killed by cervical disloca-
tion. Coagulation generally was inhibited with 1/10 vol-
ume of 10 mM NaEDTA, pH 7.5, already present in the
syringe. The mice were killed by cervical dislocation in
order to avoid any effect of anaesthetic chemicals on
blood parameters. The wild type and mutant mice were
matched regarding their age, weight and sex. The daytime
of blood collection, sampling site and collection method
were kept constant during all experiments. A typical
murine blood sample volume consisted of 550 µl, with
variations ranging from 200 µl to 900 µl. Human blood
samples from the authors were collected by vein puncture
using common EDTA-monovettes (Sarstedt).
We performed our studies using well standardized sam-
pling conditions, as differences in the blood sampling
site, for example between tail and heart, show large
changes in all cell type counts. First and second sample
draw affect blood measurements, too [22]. Also the
genetic background in common laboratory and transgenic
mice affects the phenotype. A change from one strain to
another may protect mice from effects of the primarily
induced genetic defect. For example, BALB/c mice have a
significantly increased velocity of platelet aggregation as
compared to 129Sv mice, which were used throughout
this study [23].
Self forming iodixanol density gradients of human red 
blood cells
The subcellular distribution of annexin A7 was addressed
according to [24]. Red blood cells were centrifuged and
washed in isotonic buffered salt solution, collected in ice
cold lysis buffer (20 mM Hepes, pH 7.4, 200 µM CaCl2,
0.25 M sucrose, and proteinase inhibitors (Roche)),
homogenized by a loosely fitting dounce homogenizer
and additional passages through a 22 gauge needle. A 50
% iodixanol solution was established by mixing Optiprep
solution (60 % iodixanol; Sigma) with buffer (120 mM
Hepes, pH 7.4, 1.2 mM CaCl2, 0.25 M sucrose). Seven
parts of this 50 % iodixanol solution were mixed with
thirteen parts of the red blood cell solution, generating a
gradient solution containing 17.5 % iodixanol. The mix-
ture was filled into a centrifuge tube underlayed by cush-
ions of 30 % and 35 % iodixanol and centrifuged for 3
hours at 270,000 × g in a SW41 Ti swing out rotor (Beck-
man) to achieve a nearly linear density gradient
(approximately 1.06 g/ml to 1.20 g/ml) [24]. Fractions of
0.6 ml were collected from the top of the gradient by a 1
ml syringe without using a needle and immediately frozen
in liquid nitrogen for further use.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/8
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Exovesicle generation from human and murine red blood 
cells
Red blood cells naturally can form hemoglobin contain-
ing exovesicles. In vitro these vesicle formation is Ca2+
induced. Freshly collected lithium-heparin anticoagulated
blood samples were centrifuged for 5 minutes at 400 × g
and 4°C. The erythrocytes were washed five times with 20
mM Hepes, pH 7.5, and 150 mM NaCl (washing buffer).
A volume of 500 µl washed red blood cells were com-
bined with 3 ml of vesiculation buffer (20 mM Hepes, pH
7.5, 150 mM NaCl, 1 mM CaCl2 adjusted to 5 µM Ca2+
ionophore A23187) and incubated for 30 minutes at
37°C. After incubation EDTA was added to the solution to
a final concentration of 5 mM and centrifuged for 5 min-
utes at 400 × g and 4°C. The supernatant was collected
and centrifuged for 20 minutes at 15,000 × g and 4°C. The
resulting pellet was resuspended in washing buffer and
centrifuged at 400 × g again to collect a supernatant
enriched with red blood cell microvesicles. The superna-
tant of the 15,000 × g step was further centrifuged for 60
minutes at 100,000 × g and 4°C. The final pellet of this
step was resuspended in washing buffer and centrifuged at
15,000 × g again to purify a supernatant enriched in
nanovesicles according to [7,20]. The vesicles were
assayed for acetylcholine esterase activity and used for fur-
ther analysis.
Acetylcholine esterase assay
A 30 µl sample of red blood cell vesicles was mixed with
an equal volume of buffer (20 mM Hepes, pH 7.6, 150
mM NaCl, 0.5 % Triton X-100), vortexed and incubated
for 5 minutes at 37°C. Subsequently 640 µl sodium phos-
phate buffer (100 mM Na2PO4, pH 7.6), 50 µl DTNB
(5,5'-dithiobis-(2-nitrobenzoic acid), 10 mM in sodium
phosphate buffer), and 50 µl acetylthiocholine chloride
(12,5 mM in H2O) were added. The reaction took place at
room temperature and was measured photometrically at a
wavelength of 405 nm according to the Ellmann' method
[25].
Determination of the osmotic resistance of red blood cells
A Na2HPO4/NaH2PO4 buffered NaCl gradient (pH 7.4)
comprised of the following NaCl steps was used for this
assay: 0.90%, 0.65%, 0.60%, 0.55%, 0.50%, 0.45%,
0.40%, 0.35%, 0.30%, 0.10%. For each step 5 ml of the
gradient step solution and 50 µl blood sample were care-
fully inverted four times and incubated for 30 minutes in
the dark. Samples were carefully inverted again and centri-
fuged at 1,500 × g for 10 minutes. From 1 ml supernatant
of each step the extinction at 546 nm wavelength was
measured. The experiment was performed at room
temperature.
Platelet aggregation assay
Approximately 500 µl of murine blood were centrifuged
at 200 × g for 15 minutes. The resulting supernatants were
transferred to new tubes and used as platelet rich plasma
(PRP). The platelet aggregation measurements were done
according to the method developed by Born and Cross
[26] using an APACT photometer (Labor, Ahrendsburg,
FRG) and the APACT software (APACT 1.4). Subsequently
samples of the PRP were adjusted with buffer (5 mM
Hepes, 150 mM NaCl, pH 7.3) to 250,000 platelets/µl. A
constant platelet count was used throughout allowing
comparisons between wild type and knock out murine
and human samples. 250 µl adjusted platelets were pre-
warmed to 37°C and used in the assay, and the aggrega-
tion process was started by adding 25 µl of a prewarmed
16.5 mg/ml ristocetin solution (DiaMed Diagnostica,
Bensheim, FRG; concentration in the assay: 1.5 mg/ml), a
reagent which worked reliably in our hands with mouse
and human platelets. Each murine assay represents a dif-
ferent animal. Analyses of human blood samples were
performed as described in the manufacturer's protocol.
Several repeated measurements were done per human
individual to control the reproducibility. The acquired
aggregation curve data, measured as ascending degree of
transmission, were analysed for maximal slope values,
while the maximal aggregation amplitude of every single
curve was set to 100 %. In general, all platelet procedures
were done at 22°C within four hours after collecting the
blood sample.
Miscellaneous methods
For standard haematopoetic measurements and cell
counts on murine and human blood samples about 300
µl of blood were analysed with an ADVIA 120 electronic
cell counter (Bayer). With this equipment red blood cells
and platelets are "transformed" into spherical bodies
without changing their volume. Therefore number and
volume of red blood cells and platelets are not calculated
values, but directly measured values. The following data
were statistically analysed: leucocytes, red blood cells,
haemoglobin, haematocrit, mean cellular volume, mean
cellular haemoglobin, mean cellular haemoglobin
concentration, platelet number, neutrophiles, lym-
phocytes, monocytes, eosinophiles, basophiles.
Peptide mass fingerprinting was performed on a Bruker
Reflex IV MALDI-TOF mass spectrometer. Recombinant
annexin A7 was purified according to [27], F-actin-bind-
ing of recombinant annexin A7 was done as described
[28]. SDS-PAGE and western blotting were done as
described [29,30]. Detection in immunoblots was with
enhanced chemiluminescence [17]. Antibodies employed
were mab 203–217 directed against mouse annexin A7
core domain [5] and a polyclonal rabbit anti-sorcin anti-
body [31].BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/8
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For statistical analyses the following tests were performed:
David et al. range test to ensure samples are from a normal
distribution, F-test looking for a samples' homoscedas-
city, Student's T-test to judge if samples of different groups
have a different mean value and are parts from different
normal distributions. The exact probability values and the
significance of an analysis are indicated when the experi-
ments are described.
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